Ipamorelin questions about routes and combinations
A few recurring questions become easier to answer once the route and the measured outcome are specified.
Ipamorelin half-life
The healthy-men intravenous study reported a terminal half-life of approximately 2 hours and a growth hormone peak at about 40 minutes. The half-life describes elimination of the drug; the peak describes a different blood measurement. Neither number establishes when a person would notice a health improvement.
Can Ipamorelin be absorbed through the nose?
The nasal-absorption experiment in male rats reported approximately 20% bioavailability. That animal result cannot establish human exposure or the safety of a nasal preparation. That measurement makes absorption a concrete experimental question for me.
Has under-the-skin use been characterized in people?
Published human pharmacokinetic and safety characterization for subcutaneous Ipamorelin is missing. The human studies used intravenous delivery in healthy men and intravenous delivery after bowel surgery. Animal subcutaneous results and anecdotal human routines leave that gap unresolved.
Does Ipamorelin increase IGF-1?
The 15-day adult-female-rat study found increased longitudinal bone growth without a measurable increase in systemic IGF-1. A 30-day study in older adults found sustained IGF-1 elevation with GHRP-2. That study used a different peptide. The response depends on the compound and experimental setting.
Ipamorelin, muscle and abdominal fat
Controlled human trials have established neither outcome. Mouse fat-tissue findings and the ferret experiment on cisplatin-induced weight loss complicate a simple fat-loss account. Reports of a leaner look or easier recovery are anecdotal observations, without clinical evidence attributing the changes to Ipamorelin.
Hunger after Ipamorelin
Greater hunger appears in anecdotal accounts. Rat research on ghrelin and secretagogues supports a class mechanism involving appetite circuitry. A controlled human Ipamorelin appetite result is still missing, so I cannot give an expected amount of hunger or weight change.
Ipamorelin and water retention
Puffiness of fingers, ankles and the face appears in anecdotal accounts. Growth hormone can promote salt and water retention, which makes the concern biologically plausible. Those observations leave the frequency, severity and cause of Ipamorelin-associated swelling unresolved. The effects page covers the related safety questions.
What does CJC-1295 add?
It adds a GHRH-like receptor signal to Ipamorelin's ghrelin-receptor signal. Human studies with hexarelin plus GHRH and GHRP-6 plus GHRH stimulation support the broader combination rationale. A published human outcome trial of CJC-1295 plus Ipamorelin is missing.
A studied dose for the combination?
There is no established personal amount for the pair. The dosage records describe amounts given in specified studies, including their route and population. They provide no preparation steps, injection directions or personal schedule.
Why does Ipamorelin appear in discontinuation questions?
Ipamorelin never gained drug approval. Its published Phase 2 bowel trial missed the primary endpoint. FDA's compounding entries also retain safety concerns, with the 503A nomination withdrawn and the 503B Category 2 entry still present on the page current as of April 22, 2026. This history concerns an investigational substance and compounding review, rather than withdrawal of an approved medicine.